BRWM
CTXR icon

B. Riley Wealth Management’s Citius Pharmaceuticals CTXR Stock Holding History

B. Riley Wealth Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-760
Closed -$66K – 640
2021
Q2 		$66K Buy
+760
New +$45.7K 0.01% 416

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

B. Riley Wealth Management's CTXR Position: Q3 2021 in Review

B. Riley Wealth Management sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 760 shares — an estimated $66K sold.

B. Riley Wealth Management first reported a position in CTXR in Q2 2021 and held it in 1 quarter. The position peaked at $66K in Q2 2021. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

  • B. Riley Wealth Management reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • B. Riley Wealth Management sold 760 Citius Pharmaceuticals shares in Q3 2021, an estimated $66K.
  • B. Riley Wealth Management first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • B. Riley Wealth Management's Citius Pharmaceuticals position peaked at $66K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on B. Riley Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.